Loading...
menu
Search
AI Chat
AI Strategies
Products
Markets
News
Resources
Pricing
Home
ETF
OBIO
OBIO
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
OBIO News
Orchestra BioMed and Medtronic Collaborate on AVIM Therapy Development for Hypertension
Dec 08 2025
Globenewswire
Orchestra BioMed and Medtronic Collaborate on AVIM Therapy Development
Dec 08 2025
Newsfilter
Orchestra BioMed Grants 151,250 Stock Options to 12 New Employees
Nov 26 2025
Newsfilter
Orchestra BioMed to Attend Upcoming Conferences for Institutional Investors
Nov 11 2025
Newsfilter
Orchestra BioMed Holdings Reports Increased Loss in Q3
Nov 10 2025
NASDAQ.COM
Orchestra BioMed announces secondary offering of approximately 8 million shares
Nov 03 2025
SeekingAlpha
Applied Materials Analyst Changes Stance; Check Out Wednesday's Top 5 Downgrades
Aug 20 2025
Benzinga
Chardan Capital Maintains Buy on Orchestra BioMed Hldgs, Maintains $20 Price Target
Aug 13 2025
Benzinga
Orchestra BioMed Reports Second Quarter 2025 Financial Results and Highlights Recent Business Updates
Aug 12 2025
Newsfilter
Orchestra BioMed Secures Over $111 Million in Proceeds and Committed Capital Following Completion of Strategic Transactions and Concurrent Public and Private Equity Offerings
Aug 05 2025
Newsfilter
Vivasure Medical Submits PMA Application for PerQseal® Elite and Secures Expanded Venous Indication in Europe
Jun 24 2025
Newsfilter
Orchestra BioMed Showcases AVIM Therapy as Purpose-Built Solution for Hypertensive Heart Disease at CSI Frankfurt 2025
Jun 18 2025
Newsfilter
Chardan Capital Maintains Buy on Orchestra BioMed Hldgs, Maintains $20 Price Target
May 13 2025
Benzinga
Orchestra BioMed Holdings, Inc. (OBIO) Reports Q1 Loss, Tops Revenue Estimates
May 12 2025
NASDAQ.COM
Orchestra BioMed's AVIM Therapy Global Intellectual Property Estate Reaches 137 Issued Patents for the Treatment of Hypertension and Heart Failure
May 07 2025
Newsfilter
Barclays Maintains Overweight on Orchestra BioMed Hldgs, Lowers Price Target to $12
May 05 2025
Benzinga
Show More News
